{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:46:16Z","timestamp":1770835576205,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T00:00:00Z","timestamp":1278547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T00:00:00Z","timestamp":1278547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s12325-010-0045-2","type":"journal-article","created":{"date-parts":[[2010,7,11]],"date-time":"2010-07-11T21:57:29Z","timestamp":1278885449000},"page":"495-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors"],"prefix":"10.1007","volume":"27","author":[{"given":"Hiu-yan","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley B.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,8]]},"reference":[{"key":"45_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.7164\/antibiotics.28.727","volume":"28","author":"S.N. Sehgal","year":"1975","unstructured":"Sehgal SN, Baker H, V\u00e9zina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28:727\u2013732.","journal-title":"J Antibiot (Tokyo)"},{"key":"45_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0305-7372(81)80006-0","volume":"8","author":"J. Douros","year":"1981","unstructured":"Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev. 1981;8:63\u201387.","journal-title":"Cancer Treat Rev."},{"key":"45_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000111501","volume":"87","author":"S. Grozinsky-Glasberg","year":"2008","unstructured":"Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuroendocrine tumour cell Line. Neuroendocrinology. 2008;87:168\u2013181.","journal-title":"Neuroendocrinology"},{"key":"45_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11912-009-0028-0","volume":"11","author":"J.A. Chan","year":"2009","unstructured":"Chan JA, Kulke MH. Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep. 2009;11:193\u2013199.","journal-title":"Curr Oncol Rep."},{"key":"45_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S. Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525\u2013537.","journal-title":"Ann Oncol."},{"key":"45_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2122. V.2.2010. Available at: www.nccn.org. Accessed January 24, 2010."},{"key":"45_CR7","first-page":"CD001425","volume":"3","author":"C. Coppin","year":"2004","unstructured":"Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2004;3:CD001425.","journal-title":"Cochrane Database Syst Rev."},{"key":"45_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"R.J. Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u2013124.","journal-title":"N Engl J Med."},{"key":"45_CR9","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"R.J. Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584\u20133590.","journal-title":"J Clin Oncol."},{"key":"45_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B. Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125\u2013134.","journal-title":"N Engl J Med."},{"key":"45_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","volume":"28","author":"T.E. Hutson","year":"2010","unstructured":"Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28:475\u2013480.","journal-title":"J Clin Oncol."},{"key":"45_CR12","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B. Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103\u20132111.","journal-title":"Lancet"},{"key":"45_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G. Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271\u20132281.","journal-title":"N Engl J Med."},{"key":"45_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"R.J. Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449\u2013456.","journal-title":"Lancet"},{"key":"45_CR15","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. Published online June 14, 2010.","DOI":"10.1002\/cncr.25219"},{"key":"45_CR16","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B. Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312\u20133318.","journal-title":"J Clin Oncol."},{"key":"45_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1359-6349(09)71464-8","volume":"7","author":"D. Wiederkehr","year":"2009","unstructured":"Wiederkehr D, Howe CJ, Casciano R, et al. Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analyses from the RECORD-1 phase 3 trial. Eur J Cancer Suppl. 2009;7:432.","journal-title":"Eur J Cancer Suppl."},{"key":"45_CR18","doi-asserted-by":"publisher","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","volume":"12","author":"P.H. Patel","year":"2006","unstructured":"Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12:7215\u20137220.","journal-title":"Clin Cancer Res."},{"key":"45_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMe068263","volume":"356","author":"J. Brugarolas","year":"2007","unstructured":"Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med. 2007;356:185\u2013187.","journal-title":"N Engl J Med."},{"key":"45_CR20","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/cncr.22677","volume":"109","author":"A.J. Pantuck","year":"2007","unstructured":"Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257\u20132267.","journal-title":"Cancer"},{"key":"45_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.juro.2006.08.076","volume":"177","author":"V.A. Robb","year":"2007","unstructured":"Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol. 2007;177:346\u2013352.","journal-title":"J Urol."},{"key":"45_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2407-9-161","volume":"9","author":"E. Juengel","year":"2009","unstructured":"Juengel E, Engler J, Natsheh I, et al. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer. 2009;9:161.","journal-title":"BMC Cancer"},{"key":"45_CR23","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/cncr.24280","volume":"115","author":"R.J. Amato","year":"2009","unstructured":"Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115:2438\u20132446.","journal-title":"Cancer"},{"key":"45_CR24","unstructured":"Porta C, Ravaud A, Osanto S, et al. Recommendations for adverse event management in patients with renal cell carcinoma treated with everolimus: safety data from the RECORD-1 trial. Poster presented at the 8th International Kidney Cancer Symposium, September 25\u201326, 2009, Chicago, IL, USA."},{"key":"45_CR25","unstructured":"EAU. Guidelines on Renal Cell Carcinoma. European Association of Urology 2010. Available at: www.uroweb.org. Accessed June 14, 2010."},{"issue":"Suppl4","key":"45_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/annonc\/mdp137","volume":"20","author":"B. Escudier","year":"2009","unstructured":"Escudier B, Kataja V; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):81\u201382.","journal-title":"Ann Oncol."},{"key":"45_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2008.12.010","volume":"45","author":"T.M. de Reijke","year":"2009","unstructured":"de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009;45:765\u2013773.","journal-title":"Eur J Cancer"},{"key":"45_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrd2871","volume":"8","author":"P.A. J\u00e4nne","year":"2009","unstructured":"J\u00e4nne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009;8:709\u201323.","journal-title":"Nat Rev Drug Discov."},{"key":"45_CR29","doi-asserted-by":"crossref","unstructured":"Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. J Urol. 2010; March 9 [Epub ahead of print]","DOI":"10.1016\/j.urology.2009.12.031"},{"key":"45_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.juro.2009.02.119","volume":"182","author":"M.P. Sablin","year":"2009","unstructured":"Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29\u201334.","journal-title":"J Urol."},{"key":"45_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cncr.24009","volume":"115","author":"A.Z. Dudek","year":"2009","unstructured":"Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61\u201367.","journal-title":"Cancer"},{"key":"45_CR32","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1200\/JCO.2009.22.6480","volume":"27","author":"G. Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Carten\u00ec G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469\u20134474.","journal-title":"J Clin Oncol."},{"key":"45_CR33","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1200\/jco.2008.26.15_suppl.5123","volume":"26","author":"D.R. Shepard","year":"2008","unstructured":"Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol. 2008;26:5123.","journal-title":"J Clin Oncol."},{"key":"45_CR34","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"J.C. Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u20133072.","journal-title":"J Clin Oncol."},{"key":"45_CR35","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A. Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656\u20134663.","journal-title":"J Clin Oncol."},{"key":"45_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.critrevonc.2009.01.008","volume":"72","author":"G. Capurso","year":"2009","unstructured":"Capurso G, Fazio N, Festa S, et al. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Crit Rev Oncol Hematol. 2009;72:110\u2013124.","journal-title":"Crit Rev Oncol Hematol."},{"key":"45_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E. Missiaglia","year":"2010","unstructured":"Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28:245\u2013255.","journal-title":"J Clin Oncol."},{"key":"45_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.beem.2007.01.006","volume":"21","author":"J.C. Yao","year":"2007","unstructured":"Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007;21:163\u2013172.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"45_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1677\/ERC-08-0142","volume":"16","author":"D. Dworakowska","year":"2009","unstructured":"Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer. 2009;16:45\u201358.","journal-title":"Endocr Relat Cancer"},{"key":"45_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000100057","volume":"85","author":"K. Zitzmann","year":"2007","unstructured":"Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology. 2007;85:54\u201360.","journal-title":"Neuroendocrinology"},{"key":"45_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","volume":"70","author":"V. Cerovac","year":"2010","unstructured":"Cerovac V, Monteserin-Garcia J, Rubinfeld H, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 2010;70:666\u2013674.","journal-title":"Cancer Res."},{"key":"45_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mce.2009.09.027","volume":"315","author":"S. Grozinsky-Glasberg","year":"2010","unstructured":"Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, et al. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol. 2010;315:87\u201394.","journal-title":"Mol Cell Endocrinol."},{"issue":"18S","key":"45_CR43","first-page":"582s","volume":"25","author":"D. H\u00f6rsch","year":"2007","unstructured":"H\u00f6rsch D, Tielke S, Schrader J. Expression and activation of mTOR in neuroendocrine tumors. Effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation and signalling in neuroendocrine cell lines [abstract]. J Clin Oncol. 2007;25(18S):582s.","journal-title":"J Clin Oncol."},{"issue":"Suppl1","key":"45_CR44","first-page":"S15","volume":"452","author":"L. Righi","year":"2008","unstructured":"Righi L, Volante M, Tavaglione V, et al. Mammalian target of rapamycin (MTOR) signaling activation patterns in neuroendocrine tumors of the lung. Virchows Arch. 2008;452(Suppl 1):S15.","journal-title":"Virchows Arch."},{"key":"45_CR45","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"J.C. Yao","year":"2008","unstructured":"Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311\u20134318.","journal-title":"J Clin Oncol."},{"key":"45_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"J.C. Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69\u201376.","journal-title":"J Clin Oncol."},{"key":"45_CR47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1056\/NEJMc0806740","volume":"360","author":"M.H. Kulke","year":"2009","unstructured":"Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009;360:195\u2013197.","journal-title":"N Engl J Med."},{"key":"45_CR48","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1210\/jc.2009-0788","volume":"94","author":"M.E. Bourcier","year":"2009","unstructured":"Bourcier ME, Sherrod A, DiGuardo M, Vinik AI. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab. 2009;94:3157\u20133162.","journal-title":"J Clin Endocrinol Metab."},{"key":"45_CR49","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1097-2765(00)80093-3","volume":"1","author":"I.B. Leibiger","year":"1998","unstructured":"Leibiger IB, Leibiger B, Moede T, Berggren PO. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor\/PI-3 kinase\/p70 s6 kinase and CaM kinase pathways. Mol Cell. 1998;1:933\u2013938.","journal-title":"Mol Cell."},{"key":"45_CR50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1046\/j.1463-1326.2001.00150.x","volume":"3","author":"D.K. Fuhrer","year":"2001","unstructured":"Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab. 2001;3:393\u2013402.","journal-title":"Diabetes Obes Metab."},{"key":"45_CR51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1055\/s-0029-1220687","volume":"41","author":"M.R. Druce","year":"2009","unstructured":"Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;41:697\u2013702.","journal-title":"Horm Metab Res."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-010-0045-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12325-010-0045-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:19:15Z","timestamp":1724411955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-010-0045-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0045-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,8]]},"assertion":[{"value":"30 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2010","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}